North America is anticipated to dominate the market of Leukocyte adhesion deficiency treatment by reaching market valuation of US$ 6.1 billion by end of the forecast period.
The global Leukocyte Adhesion Deficiency Management Market revenue is expected to reach a valuation of US$ 8.09 billion in 2023 and is projected to reach US$ 15.2 billion by 2033, trailing a CAGR of 6.51% during the forecast period. Surging number of research and development activities for improving the effectiveness of immunodeficiency therapeutics is expected to drive growth of the market during the forecast period.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16552
For instance, according to an article published by National Institute of Health (NIH) in May 2021, an investigational research study conducted in in US and UK and supported by NIH showed that., 96% of children receiving new experimental lentiviral gene therapy for immunodeficiency diseases reported restored immune function.
Increasing advancements of technology in the field of genetics is anticipated to drive growth of the global leukocyte adhesion deficiency therapeutics market over the forecast period. For instance, according to an article published in the Genes & Diseases international scientific journal in March 2020, recent technological advancements such as next generation sequencing (NGS) have enabled researchers to explore newer genetic variations related to common variable immunodeficiency (CVID) in order to improve its diagnosis.
On the other hand, growing number of various immunodeficiency diseases is also key factor driving the market growth. For instance, according to an article published in January 2021, titled ‘Primary immunodeficiency diseases treated with immunoglobulin and associated comorbidities’, it has been observed that chronic obstructive pulmonary disease-asthma (51.5%) was statistically significantly more common as a comorbid diagnosis in the primary immunodeficiency disease population, followed by rheumatoid disease (14%), deficiency anemia (11.8%), hypothyroidism (21.2%), lymphoma (16.7%), neurologic disorders (9.7%), arrhythmias (19.9%), electrolyte disorders (23.6%), coagulopathies (16.9%), and weight loss (8.4%). These
For any queries linked with the report, ask an analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16552
Key Takeaways
“Mounting research and development activities and increasing practices of utilizing stem-cell transplantation therapies to treat leukocyte adhesion deficiency will propel market during the forecast period,” comments an FMI Analyst
Competitive Landscape
The global Leukocyte Adhesion Deficiency Management market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Orpha Labs, Avalo Therapeutics, Inc., Rocket Pharmaceuticals Inc., Sigma-Aldrich, Aspen Neuroscience, Magenta Therapeutics, Rubius Therapeutics, Enochian Biosciences, Sana Biotechnology, Vertex Pharmaceuticals. Some recent developments in the market are:
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global Leukocyte Adhesion Deficiency Management market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/16552
Key Segments Profiled in the Leukocyte Adhesion Deficiency Management Industry Survey
By Treatment:
By End Users:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market.
Jun 13, 2023